We analyzed the outcomes of 146 severe aplastic anemia (SAA) patients who received a combination of haploidentical haematopoietic stem cell transplantation (haplo-HSCT) and an unrelated cord-blood (UCB) unit between September 2011 and December 2017. One hundred and seventeen patients underwent transplantation as first-line therapy. Seven patients experienced early mortality, and among the evaluable 139 patients, one patient experienced primary graft failure (GF), while the other 138 patients achieved successful haploidentical donor engraftment; additionally, three patients experienced secondary GF. Six patients demonstrated delayed platelet recovery, and three patients demonstrated platelet GF. The median time for myeloid and platelet engraftment was 11 (range: 9–28) days and 15 (range: 9–330) days, respectively. With a median follow-up of 40 (range: 18–93) months, the cumulative incidences were 31.43% and 10.00% for grades II–IV and grades III–IV acute graft-versus-host disease (GVHD), respectively. The cumulative incidences of chronic GVHD (cGVHD) and moderate–severe cGVHD were 36.23% and 11.71%, respectively. There was no patient relapse. The probabilities of 4-year overall survival and GVHD-free, failure-free survival were 81.4 ± 3.3% and 69.2 ± 3.9%, respectively. These encouraging preliminary results indicated that haplo-HSCT combined with the infusion of UCB is a feasible choice for SAA patients without matched donors.

我们分析了2011年9月至2017年12月间接受单倍型造血干细胞移植（haplo-HSCT）和无关脐带血（UCB）单元治疗的146例严重再生障碍性贫血（SAA）患者的结果。117例患者接受移植作为一线治疗。7例患者早期死亡，并且在139例患者中，1例患者发生了原发性移植失败（GF），而其他138例患者成功完成了单侧供体植入。另外，三名患者经历了继发性GF。6名患者表现出延迟的血小板恢复，3名患者表现出血小板GF。骨髓和血小板移植的中位时间分别为11天（9-28）天和15天（9-330）天。中位随访40个月（范围：18-93个月），II-IV级和III-IV级急性移植物抗宿主病（GVHD）的累积发生率分别为31.43％和10.00％。慢性GVHD（cGVHD）和中重度cGVHD的累积发生率分别为36.23％和11.71％。没有患者复发。4年总生存率和无GVHD，无衰竭生存率分别为81.4±3.3％和69.2±3.9％。这些令人鼓舞的初步结果表明，对于没有匹配供体的SAA患者，单倍HSCT结合UCB输注是可行的选择。慢性GVHD（cGVHD）和中重度cGVHD的累积发生率分别为36.23％和11.71％。没有患者复发。4年总生存率和无GVHD，无衰竭生存率分别为81.4±3.3％和69.2±3.9％。这些令人鼓舞的初步结果表明，对于没有匹配供体的SAA患者，单倍HSCT结合UCB输注是可行的选择。慢性GVHD（cGVHD）和中重度cGVHD的累积发生率分别为36.23％和11.71％。没有患者复发。4年总生存率和无GVHD，无衰竭生存率分别为81.4±3.3％和69.2±3.9％。这些令人鼓舞的初步结果表明，对于没有匹配供体的SAA患者，单倍HSCT联合UCB灌注是可行的选择。